Thomas J. O'Hare, PhD

Research Interests

  • Design and Synthesis of Targeted Cancer Drugs
  • Tyrosine Kinase Activating Mutations
  • Leukemia, Myeloid, Philadelphia-Positive
  • Drug Resistance

Labs

Lab Website

Languages

  • English

Academic Information

  • Departments: Internal Medicine - Research Professor
  • Divisions: Hematology/BMT
  • Cancer Center Programs: Cell Response & Regulation

Academic Office Information

  • 801-585-0256
  • Huntsman Cancer Institute
    HCI4264
    2000 Circle of Hope, Room: HCI 4264
    Salt Lake City, UT 84112

Academic Bio

Thomas J. O'Hare, Ph.D. is a Research Professor of Medicine (career track) in the Division of Hematology and Hematologic Malignancies, Department of Internal Medicine at the University of Utah. His lab is located in the Huntsman Cancer Institute and he is a member of the Cell Response and Regulation Program. He received his B.Sc. in Chemistry from Southern Oregon University in Ashland, followed by his Ph.D. in Chemistry at the University of Washington in Seattle. Dr. O'Hare completed two Postdoctoral Fellowships: one in Chemistry at Oregon State University and one in Molecular Microbiology and Immunology at Oregon Health & Science University in Portland.

Dr. O'Hare's research focuses on Chronic Myeloid Leukemia, Acute Myeloid Leukemia and other blood cancers. He also has a research interest in non-small cell lung cancer driven by misregulated fusion kinases such as ROS1.

Education History

Type School Degree
Postdoctoral Fellowship Oregon Health & Science University
Molecular Microbiology and Immunology
Postdoctoral Fellow
Postdoctoral Fellowship Oregon State University
Chemistry
Postdoctoral Fellow
Doctoral Training University of Washington
Chemistry
Ph.D.
Undergraduate Southern Oregon University
Chemistry
B.Sc.

Selected Publications

Journal Article

  1. Than H, Qiao Y, Huang X, Yan D, Khorashad JS, Pomicter AD, Kovacsovics TJ, Marth GT, OHare T, Deininger MW (2018 Sep). Ongoing clonal evolution in chronic myelomonocytic leukemia on hypomethylating agents: a computational perspective. Leukemia, 32(9), 2049-2054.
  2. Heaton WL, Senina AV, Pomicter AD, Salama ME, Clair PM, Yan D, Bell RN, Gililland JM, Prchal JT, OHare T, Deininger MW (2018 Apr 18). Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion.LID - 10.1038/s41375-018-0131-z [doi]. (Epub ahead of print) Leukemia.
  3. Patel AB, Lange T, Pomicter AD, Conley CJ, Harrington CA, Reynolds KR, Kelley TW, OHare T, Deininger MW (2018 Apr 3). Similar expression profiles in CD34(+) cells from chronic phase chronic myeloid leukemia patients with and without deep molecular responses to nilotinib. Oncotarget, 9(25), 17889-17894.
  4. Zabriskie MS, Antelope O, Verma AR, Draper LR, Eide CA, Pomicter AD, Tran TH, Druker BJ, Tyner JW, Miles RR, Graham JM, Hwang JY, Varley KE, Toydemir RM, Deininger MW, Raetz EA, OHare T (2018 Feb). A novel AGGF1-PDGFRb fusion in pediatric T-cell acute lymphoblastic leukemia. Haematologica, 103(2), e87-e91.
  5. Qiang W, Antelope O, Zabriskie MS, Pomicter AD, Vellore NA, Szankasi P, Rea D, Cayuela JM, Kelley TW, Deininger MW, OHare T (2017 Dec). Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib. Leukemia, 31(12), 2844-2847.
  6. Eiring AM, Page BDG, Kraft IL, Mason CC, Vellore NA, Resetca D, Zabriskie MS, Zhang TY, Khorashad JS, Engar AJ, Reynolds KR, Anderson DJ, Senina A, Pomicter AD, Arpin CC, Ahmad S, Heaton WL, Tantravahi SK, Todic A, Colaguori R, Moriggl R, Wilson DJ, Baron R, OHare T, Gunning PT, Deininger MW (2017 May). Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia, 31(5), 1253-1254.
  7. Khorashad JS, Tantravahi SK, Yan D, Mason CC, Qiao Y, Eiring AM, Gligorich K, Hein T, Pomicter AD, Reid AG, Kelley TW, Marth GT, OHare T, Deininger MW (2016 Nov). Rapid conversion of chronic myeloid leukemia to chronic myelomonocytic leukemia in a patient on imatinib therapy. Leukemia, 30(11), 2275-2279.
  8. Wagle M, Eiring AM, Wongchenko M, Lu S, Guan Y, Wang Y, Lackner M, Amler L, Hampton G, Deininger MW, OHare T, Yan Y (2016 Jul). A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Leukemia, 30(7), 1493-501.
  9. Jacob T, Agarwal A, Ramunno-Johnson D, OHare T, Gonen M, Tyner JW, Druker BJ, Vu TQ (2016 Jun 20). Ultrasensitive proteomic quantitation of cellular signaling by digitized nanoparticle-protein counting. Sci Rep, 6, 28163.
  10. Zabriskie MS, Eide CA, Yan D, Vellore NA, Pomicter AD, Savage SL, Druker BJ, Deininger MW, OHare T (2016 Jun). Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia. Leukemia, 30(6), 1418-21.
  11. Drilon A, Somwar R, Wagner JP, Vellore NA, Eide CA, Zabriskie MS, Arcila ME, Hechtman JF, Wang L, Smith RS, Kris MG, Riely GJ, Druker BJ, OHare T, Ladanyi M, Davare MA (2016 May 15). A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer. Clin Cancer Res, 22(10), 2351-8.
  12. Ali AM, Gomez-Biagi RF, Rosa DA, Lai PS, Heaton WL, Park JS, Eiring AM, Vellore NA, de Araujo ED, Ball DP, Shouksmith AE, Patel AB, Deininger MW, OHare T, Gunning PT (2016 Apr 19). Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities. ChemMedChem, 11(8), 850-61.
  13. Mason CC, Khorashad JS, Tantravahi SK, Kelley TW, Zabriskie MS, Yan D, Pomicter AD, Reynolds KR, Eiring AM, Kronenberg Z, Sherman RL, Tyner JW, Dalley BK, Dao KH, Yandell M, Druker BJ, Gotlib J, OHare T, Deininger MW (2016 Apr). Age-related mutations and chronic myelomonocytic leukemia. Leukemia, 30(4), 906-13.
  14. Buetti-Dinh A, OHare T, Friedman R (2016). Sensitivity Analysis of the NPM-ALK Signalling Network Reveals Important Pathways for Anaplastic Large Cell Lymphoma Combination Therapy. PLoS ONE, 11(9), e0163011.
  15. Eiring AM, Khorashad JS, Anderson DJ, Yu F, Redwine HM, Mason CC, Reynolds KR, Clair PM, Gantz KC, Zhang TY, Pomicter AD, Kraft IL, Bowler AD, Johnson K, Partlin MM, OHare T, Deininger MW (2015 Dec). beta-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia. Leukemia, 29(12), 2328-37.
  16. Davare MA, Vellore NA, Wagner JP, Eide CA, Goodman JR, Drilon A, Deininger MW, OHare T, Druker BJ (2015 Sep 29). Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors. Proc Natl Acad Sci U S A, 112(39), E5381-90.
  17. Zabriskie MS, Vellore NA, Gantz KC, Deininger MW, OHare T (2015 Sep). Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1. Leukemia, 29(9), 1939-42.
  18. Woessner DW, Eiring AM, Bruno BJ, Zabriskie MS, Reynolds KR, Miller GD, OHare T, Deininger MW, Lim CS (2015 Aug). A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemia. Leukemia, 29(8), 1668-75.
  19. Pomicter AD, Eiring AM, Senina AV, Zabriskie MS, Marvin JE, Prchal JT, OHare T, Deininger MW (2015 Jul). Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm. Exp Hematol, 43(7), 537-45.e1-11.
  20. Khorashad JS, Eiring AM, Mason CC, Gantz KC, Bowler AD, Redwine HM, Yu F, Kraft IL, Pomicter AD, Reynolds KR, Iovino AJ, Zabriskie MS, Heaton WL, Tantravahi SK, Kauffman M, Shacham S, Chenchik A, Bonneau K, Ullman KS, OHare T, Deininger MW (2015 Mar 12). shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance. Blood, 125(11), 1772-81.
  21. Eiring AM, Page BDG, Kraft IL, Mason CC, Vellore NA, Resetca D, Zabriskie MS, Zhang TY, Khorashad JS, Engar AJ, Reynolds KR, Anderson DJ, Senina A, Pomicter AD, Arpin CC, Ahmad S, Heaton WL, Tantravahi SK, Todic A, Moriggl R, Wilson DJ, Baron R, OHare T, Gunning PT, Deininger MW (2015 Mar). Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia, 29(3), 586-597.
  22. Eiring AM, Kraft IL, Page BD, OHare T, Gunning PT, Deininger MW (2014 Dec). STAT3 as a mediator of BCR-ABL1-independent resistance in chronic myeloid leukemia. Leuk Suppl, 3(Suppl 1), S5-6.
  23. Agarwal A, Mackenzie RJ, Besson A, Jeng S, Carey A, LaTocha DH, Fleischman AG, Duquesnes N, Eide CA, Vasudevan KB, Loriaux MM, Firpo E, Cortes JE, McWeeney S, OHare T, Roberts JM, Druker BJ, Deininger MW (2014 Nov 20). BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein. Blood, 124(22), 3260-73.
  24. Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour EJ, Kornblau SM, Lipton JH, Rea D, Stenke L, Barbany G, Lange T, Hernandez-Boluda JC, Ossenkoppele GJ, Press RD, Chuah C, Goldberg SL, Wetzler M, Mahon FX, Etienne G, Baccarani M, Soverini S, Rosti G, Rousselot P, Friedman R, Deininger M, Reynolds KR, Heaton WL, Eiring AM, Pomicter AD, Khorashad JS, Kelley TW, Baron R, Druker BJ, Deininger MW, OHare T (2014 Sep 8). BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell, 26(3), 428-442.
  25. Vainstein V, Eide CA, OHare T, Shukron O, Druker BJ (2013 Nov 7). Integrating in vitro sensitivity and dose-response slope is predictive of clinical response to ABL kinase inhibitors in chronic myeloid leukemia. Blood, 122(19), 3331-4.
  26. Corbin AS, OHare T, Gu Z, Kraft IL, Eiring AM, Khorashad JS, Pomicter AD, Zhang TY, Eide CA, Manley PW, Cortes JE, Druker BJ, Deininger MW (2013 Sep 15). KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors. Cancer Res, 73(18), 5775-86.
  27. Eide CA, Druker BJ, OHare T (2013 Sep). Kinase inhibitor therapy in CML: it's what's inside that counts. Oncotarget, 4(9), 1332-3.
  28. OHare T, Eide CA, Agarwal A, Adrian LT, Zabriskie MS, Mackenzie RJ, Latocha DH, Johnson KJ, You H, Luo J, Riddle SM, Marks BD, Vogel KW, Koop DR, Apgar J, Tyner JW, Deininger MW, Druker BJ (2013 Jun 1). Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis. Cancer Res, 73(11), 3356-70.
  29. Khorashad JS, Kelley TW, Szankasi P, Mason CC, Soverini S, Adrian LT, Eide CA, Zabriskie MS, Lange T, Estrada JC, Pomicter AD, Eiring AM, Kraft IL, Anderson DJ, Gu Z, Alikian M, Reid AG, Foroni L, Marin D, Druker BJ, OHare T, Deininger MW (2013 Jan 17). BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood, 121(3), 489-98.
  30. Tyner JW, Yang WF, Bankhead A 3rd, Fan G, Fletcher LB, Bryant J, Glover JM, Chang BH, Spurgeon SE, Fleming WH, Kovacsovics T, Gotlib JR, Oh ST, Deininger MW, Zwaan CM, Den Boer ML, van den Heuvel-Eibrink MM, OHare T, Druker BJ, Loriaux MM (2013 Jan 1). Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Res, 73(1), 285-96.
  31. Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, OHare T, Hu S, Narasimhan NI, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MW, Talpaz M (2012 Nov 29). Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med, 367(22), 2075-88.
  32. Traer E, MacKenzie R, Snead J, Agarwal A, Eiring AM, OHare T, Druker BJ, Deininger MW (2012 May). Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors. Leukemia, 26(5), 1140-3.
  33. Packer LM, Rana S, Hayward R, OHare T, Eide CA, Rebocho A, Heidorn S, Zabriskie MS, Niculescu-Duvaz I, Druker BJ, Springer C, Marais R (2011 Dec 13). Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia. Cancer Cell, 20(6), 715-27.
  34. Fleischman AG, Aichberger KJ, Luty SB, Bumm TG, Petersen CL, Doratotaj S, Vasudevan KB, LaTocha DH, Yang F, Press RD, Loriaux MM, Pahl HL, Silver RT, Agarwal A, OHare T, Druker BJ, Bagby GC, Deininger MW (2011 Dec 8). TNFalpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood, 118(24), 6392-8.
  35. OHare T, Zabriskie MS, Eide CA, Agarwal A, Adrian LT, You H, Corbin AS, Yang F, Press RD, Rivera VM, Toplin J, Wong S, Deininger MW, Druker BJ (2011 Nov 10). The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Blood, 118(19), 5250-4.
  36. Eide CA, Adrian LT, Tyner JW, Mac Partlin M, Anderson DJ, Wise SC, Smith BD, Petillo PA, Flynn DL, Deininger MW, OHare T, Druker BJ (2011 May 1). The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. Cancer Res, 71(9), 3189-95.
  37. OHare T, Deininger MW, Eide CA, Clackson T, Druker BJ (2011 Jan 15). Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia. Clin Cancer Res, 17(2), 212-21.
  38. Seo JH, Wood LJ, Agarwal A, OHare T, Elsea CR, Griswold IJ, Deininger MW, Imamoto A, Druker BJ (2010 Sep 15). A specific need for CRKL in p210BCR-ABL-induced transformation of mouse hematopoietic progenitors. Cancer Res, 70(18), 7325-35.
  39. Gregory MA, Phang TL, Neviani P, Alvarez-Calderon F, Eide CA, OHare T, Zaberezhnyy V, Williams RT, Druker BJ, Perrotti D, Degregori J (2010 Jul 13). Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. Cancer Cell, 18(1), 74-87.
  40. Demehri S, OHare T, Eide CA, Smith CA, Tyner JW, Druker BJ, Deininger MW (2010 Jan). The function of the pleckstrin homology domain in BCR-ABL-mediated leukemogenesis. Leukemia, 24(1), 226-9.
  41. OHare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA 3rd, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats JA, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker BJ, Clackson T (2009 Nov 6). AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell, 16(5), 401-12.
  42. Snead JL, OHare T, Adrian LT, Eide CA, Lange T, Druker BJ, Deininger MW (2009 Oct 15). Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis. Blood, 114(16), 3459-63.
  43. Johnson KJ, Griswold IJ, OHare T, Corbin AS, Loriaux M, Deininger MW, Druker BJ (2009 Oct 13). A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice. PLoS ONE, 4(10), e7439.
  44. Tyner JW, Rutenberg-Schoenberg ML, Erickson H, Willis SG, OHare T, Deininger MW, Druker BJ, Loriaux MM (2009 Jul). Functional characterization of an activating TEK mutation in acute myeloid leukemia: a cellular context-dependent activating mutation. Leukemia, 23(7), 1345-8.
  45. Scholl B, Liu HY, Long BR, McCarty OJ, OHare T, Druker BJ, Vu TQ (2009 Jun 23). Single particle quantum dot imaging achieves ultrasensitive detection capabilities for Western immunoblot analysis. ACS Nano, 3(6), 1318-28.
  46. Tyner JW, Deininger MW, Loriaux MM, Chang BH, Gotlib JR, Willis SG, Erickson H, Kovacsovics T, OHare T, Heinrich MC, Druker BJ (2009 May 26). RNAi screen for rapid therapeutic target identification in leukemia patients. Proc Natl Acad Sci U S A, 106(21), 8695-700.
  47. OHare T, Deininger MW (2008 Dec 15). Toward a cure for chronic myeloid leukemia. Clin Cancer Res, 14(24), 7971-4.
  48. Agarwal A, Bumm TG, Corbin AS, OHare T, Loriaux M, VanDyke J, Willis SG, Deininger J, Nakayama KI, Druker BJ, Deininger MW (2008 Sep 1). Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease. Blood, 112(5), 1960-70.
  49. OHare T, Eide CA, Tyner JW, Corbin AS, Wong MJ, Buchanan S, Holme K, Jessen KA, Tang C, Lewis HA, Romero RD, Burley SK, Deininger MW (2008 Apr 8). SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. Proc Natl Acad Sci U S A, 105(14), 5507-12.
  50. Tyner JW, Walters DK, Willis SG, Luttropp M, Oost J, Loriaux M, Erickson H, Corbin AS, OHare T, Heinrich MC, Deininger MW, Druker BJ (2008 Feb 15). RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. Blood, 111(4), 2238-45.
  51. Chou CJ, OHare T, Lefebvre S, Alvarez D, Tyner JW, Eide CA, Druker BJ, Gottesfeld JM (2008). Growth arrest of BCR-ABL positive cells with a sequence-specific polyamide-chlorambucil conjugate. PLoS ONE, 3(10), e3593.
  52. OHare T, Eide CA, Deininger MW (2007 Oct 1). Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood, 110(7), 2242-9.
  53. Bradeen HA, Eide CA, OHare T, Johnson KJ, Willis SG, Lee FY, Druker BJ, Deininger MW (2006 Oct 1). Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood, 108(7), 2332-8.
  54. Griswold IJ, MacPartlin M, Bumm T, Goss VL, OHare T, Lee KA, Corbin AS, Stoffregen EP, Smith C, Johnson K, Moseson EM, Wood LJ, Polakiewicz RD, Druker BJ, Deininger MW (2006 Aug). Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol, 26(16), 6082-93.
  55. Walters DK, Mercher T, Gu TL, OHare T, Tyner JW, Loriaux M, Goss VL, Lee KA, Eide CA, Wong MJ, Stoffregen EP, McGreevey L, Nardone J, Moore SA, Crispino J, Boggon TJ, Heinrich MC, Deininger MW, Polakiewicz RD, Gilliland DG, Druker BJ (2006 Jul). Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell, 10(1), 65-75.
  56. Crossman LC, OHare T, Lange T, Willis SG, Stoffregen EP, Corbin AS, OBrien SG, Heinrich MC, Druker BJ, Middleton PG, Deininger MW (2005 Nov). A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib. Leukemia, 19(11), 1859-62.
  57. OHare T, Druker BJ (2005 Oct). BIRB-796 is not an effective ABL(T315I) inhibitor. Nat Biotechnol, 23(10), 1209-10; author reply 1210-1.
  58. OHare T, Walters DK, Stoffregen EP, Sherbenou DW, Heinrich MC, Deininger MW, Druker BJ (2005 Oct 1). Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. Clin Cancer Res, 11(19 Pt 1), 6987-93.
  59. OHare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, Cowan-Jacob SW, Lee FY, Heinrich MC, Deininger MW, Druker BJ (2005 Jun 1). In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res, 65(11), 4500-5.
  60. OHare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, Moseson EM, Rivera VM, Tang H, Metcalf CA 3rd, Bohacek RS, Wang Y, Sundaramoorthi R, Shakespeare WC, Dalgarno D, Clackson T, Sawyer TK, Deininger MW, Druker BJ (2004 Oct 15). Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood, 104(8), 2532-9.
  61. Izumikawa M, Shipley PR, Hopke JN, OHare T, Xiang L, Noel JP, Moore BS (2003 Aug). Expression and characterization of the type III polyketide synthase 1,3,6,8-tetrahydroxynaphthalene synthase from Streptomyces coelicolor A3(2). J Ind Microbiol Biotechnol, 30(8), 510-5.
  62. Yin X, OHare T, Gould SJ, Zabriskie TM (2003 Jul 17). Identification and cloning of genes encoding viomycin biosynthesis from Streptomyces vinaceus and evidence for involvement of a rare oxygenase. Gene, 312, 215-24.
  63. Moore BS, Hertweck C, Hopke JN, Izumikawa M, Kalaitzis JA, Nilsen G, OHare T, Piel J, Shipley PR, Xiang L, Austin MB, Noel JP (2002 Dec). Plant-like biosynthetic pathways in bacteria: from benzoic acid to chalcone. J Nat Prod, 65(12), 1956-62.
  64. Green F, OHare T, Blackwell A, Enns CA (2002 May 8). Association of human transferrin receptor with GABARAP. FEBS Lett, 518(1-3), 101-6.
  65. Wiens GD, OHare T, Rittenberg MB (2001 Nov 2). Recovering antibody secretion using a hapten ligand as a chemical chaperone. J Biol Chem, 276(44), 40933-9.
  66. OHare T, Wiens GD, Whitcomb EA, Enns CA, Rittenberg MB (1999 Jul 1). Cutting edge: proteasome involvement in the degradation of unassembled Ig light chains. J Immunol, 163(1), 11-4.
  67. Brown M, Wiens GD, OHare T, Stenzel-Poore MP, Rittenberg MB (1999 Feb). Replacements in the exposed loop of the T15 antibody VH CDR2 affect carrier recognition of PC-containing pathogens. Mol Immunol, 36(3), 205-11.
  68. OHare T, Rittenberg MB (1998 Sep 1). A simple method for determining K(A)s of both low and high affinity IgG antibodies. J Immunol Methods, 218(1-2), 161-7.
  69. Gould SJ, OHare T, Seaton P, Soodsma J, Tang Z (1996 Jul). Kinamycin acetyltransferase I from Streptomyces murayamaensis, an apparently large, membrane-associated enzyme. Bioorg Med Chem, 4(7), 987-94.
  70. Ghomashchi F, OHare T, Clary D, Gelb MH (1991 Jul 23). Interfacial catalysis by phospholipase A2: evaluation of the interfacial rate constants by steady-state isotope effect studies. Biochemistry, 30(29), 7298-305.

Review

  1. Tantravahi SK, Guthula RS, OHare T, Deininger MW (2017 Oct). Minimal Residual Disease Eradication in CML: Does It Really Matter? [Review]. Curr Hematol Malig Rep, 12(5), 495-505.
  2. Patel AB, OHare T, Deininger MW (2017 Aug). Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors. [Review]. Hematol Oncol Clin North Am, 31(4), 589-612.
  3. OHare T (2016 Oct 15). A Decade of Nilotinib and Dasatinib: From In Vitro Studies to First-Line Tyrosine Kinase Inhibitors. [Review]. Cancer Res, 76(20), 5911-5913.
  4. Eide CA, OHare T (2015 Jun). Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors. [Review]. Curr Hematol Malig Rep, 10(2), 158-66.
  5. OHare T, Zabriskie MS, Eiring AM, Deininger MW (2012 Jul 24). Pushing the limits of targeted therapy in chronic myeloid leukaemia. [Review]. Nat Rev Cancer, 12(8), 513-26.
  6. OHare T, Eide CA, Deininger MW (2008 Jun). New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check. [Review]. Expert Opin Investig Drugs, 17(6), 865-78.
  7. Snead JL, OHare T, Eide CA, Deininger MW (2008 Mar). New strategies for the first-line treatment of chronic myeloid leukemia: can resistance be avoided? [Review]. Clin Lymphoma Myeloma, 8 Suppl 3, S107-17.
  8. OHare T, Eide CA, Deininger MW (2007 Mar). Bcr-Abl kinase domain mutations and the unsettled problem of Bcr-AblT315I: looking into the future of controlling drug resistance in chronic myeloid leukemia. [Review]. Clin Lymphoma Myeloma, 7 Suppl 3, S120-30.
  9. OHare T, Corbin AS, Druker BJ (2006 Feb). Targeted CML therapy: controlling drug resistance, seeking cure. [Review]. Curr Opin Genet Dev, 16(1), 92-9.
  10. OHare T, Walters DK, Deininger MW, Druker BJ (2005 Feb). AMN107: tightening the grip of imatinib. [Review]. Cancer Cell, 7(2), 117-9.
  11. Wiens GD, Roberts VA, Whitcomb EA, OHare T, Stenzel-Poore MP, Rittenberg MB (1998 Apr). Harmful somatic mutations: lessons from the dark side. [Review]. Immunol Rev, 162, 197-209.

Book Chapter

  1. Agarwal A, OHare T, Deininger M (). CXCR4 antagonists for the treatment of CML. In Fruehauf S, Zeller WJ, Calandra, G (Eds.), Novel developments in stem cell mobilization: Focus on CXCR4 (XIV, pp. 351-367). Springer.
  2. OHare T, Eide CA, Deininger MW (). A new generation of drugs in cancer treatment: Molecularly targeted therapies. In Stein GS, Pardee AB (Eds.), The biology and treatment of cancer: Understanding cancer (pp. 193-222). Wiley-Blackwell.

Editorial

  1. Carella AM, Branford S, Deininger MW, Mahon FX, Saglio G, Eiring AM, Khorashad J, OHare T, Goldman JM (). What challenges remain in chronic myeloid leukemia research? Haematologica, 98(8), 1168-1172.
  2. Khorashad JS, Deininger MW, OHare T (2013 Jan). New concepts for CML clonality. Oncotarget, 4(1), 7-8.
  3. OHare T, Eide CA, Deininger MW (2008 Jul 2). Persistent LYN signaling in imatinib-resistant, BCR-ABL-independent chronic myelogenous leukemia. J Natl Cancer Inst, 100(13), 908-9.

Video